Treprostinil

CHEMBL1237119 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

390.5 g/mol

LogP

4.5

Phase

4

Treprostinil is a synthetic stable analog of prostacyclin (PGI2) that binds to prostacyclin receptors (IP receptors) on pulmonary vascular smooth muscle cells, activating adenylyl cyclase, increasing intracellular cAMP, and causing potent pulmonary and systemic vasodilation while also inhibiting platelet aggregation and vascular smooth muscle cell proliferation. It is approved for pulmonary arterial hypertension (PAH) via multiple routes (subcutaneous, intravenous, inhaled, oral) and is under investigation for COPD-associated pulmonary hypertension. Its chemical stability distinguishes it from natural prostacyclin, allowing storage at room temperature.

Berat Molekul

390,5000 g/mol

LogP

4,50

TPSA

87,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Cardiovascular Disease Pain Management Chronic Obstructive Pulmonary Disease Hypertension Chronic Pain Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O

InChI

InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1

Molecular Formula

C23H34O5

HBD / HBA

3 / 5

Ikatan yang Dapat Dirotasi

10

Atom Berat

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Treprostinil is a synthetic stable analog of prostacyclin (PGI2) that binds to prostacyclin receptors (IP receptors) on pulmonary vascular smooth muscle cells, activating adenylyl cyclase, increasing intracellular cAMP, and causing potent pulmonary and systemic vasodilation while also inhibiting platelet aggregation and vascular smooth muscle cell proliferation. It is approved for pulmonary arterial hypertension (PAH) via multiple routes (subcutaneous, intravenous, inhaled, oral) and is under investigation for COPD-associated pulmonary hypertension. Its chemical stability distinguishes it from natural prostacyclin, allowing storage at …

Yes, Treprostinil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237119. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918140. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Treprostinil di PillFYI

Struktur

Data Cepat

Rumus: C23H34O5
Sinonim: 5

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.